Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-91P (RNA, U6 small nuclear 91, pseudogene) is annotated as a pseudogene of the U6 small nuclear RNA family[2][4]. U6 small nuclear RNA (snRNA) is an essential non-coding RNA component of the spliceosome, required for the excision of introns from pre-mRNA in eukaryotes[3][1]. However, RNU6-91P itself is a pseudogene—a non-functional genomic copy—meaning it does not produce a functional RNA product and does not participate in biological processes such as RNA splicing[2]. Pseudogenes in the U6 snRNA family are common in vertebrates and often serve as evolutionary markers or indicators of retrotransposition dynamics, but do not have known biological activities or disease roles[5]. There are no known drugs or mechanisms targeting this pseudogene, nor is it a therapeutic or diagnostic target. This entry is considered incorrect as a therapeutic target, as RNU6-91P is a pseudogene and not an active receptor, enzyme, or signaling molecule[2][4][5]. All essential functional or disease-related roles, and drug interactions, pertain to the canonical U6 snRNA, not to its pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 91, pseudogene (RNU6-91P).